The role of the inhibitor of apoptosis protein (IAP) family in hematological malignancies;Rola białek z rodziny inhibitora apoptozy (IAP) w chorobach rozrostowych UKładu krwiotwórczego

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 62, Issue , 2008, Pages 55-63

  Grzybowska Izydorczyk, Olga ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; CIAP1; CIAP2; Hematological malignancies; HtrA2 Omi; Inhibitors of apoptosis; Regulation of apoptosis; Smac DIABLO; Survivin; XIAP

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN;

ANIMAL; APOPTOSIS; BLOOD DISEASE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; REVIEW;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS;

EID: 40749104690     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., Dombret H., Reyes F., Diebold J., Gisselbrecht C., Salles G., Altieri D.C., Molina T.J.: Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood, 2000; 96: 1921-1925
2. Akyurek N., Ren Y., Rassidakis G.Z., Schlette E.J., Medeiros L.J.: Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer, 2006; 107: 1844-1851
3. Badran A., Yoshida A., Wano Y., Imamura S., Kawai Y., Tsutani H., Inuzuka M., Ueda T.: Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res., 2003; 23: 589-592
4. Badran A., Yoshida A., Wano Y., Mutoh M., Imamura S., Yamashita T., Tsutani H., Inuzuka M., Ueda T.: Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int. J. Oncol., 2003; 22: 59-64
5. Bellamy C.O., Malcomson R.D., Harrison D.J., Wyllie A.H.: Cell death in health and disease: The biology and regulation of apoptosis. Semin. Cancer Biol., 1995; 6: 3-16
6. Bielak-Zmijewska A.: Mechanizmy opornos̈ci komórek nowotworowych na apoptozę. Kosmos. Problemy Nauk Biologicznych, 2003; 52: 157-171
7. Bilim V., Kasahara T., Hara N., Takahashi K., Tomita Y.: Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer, 2003; 103: 29-37
8. Caligaris-Cappio F.: New insight into the biology of B-chronic lymphocytic leukemia. 41st ASH Annual Meeting. New Orleans, 4-7. Dec. 1999
9. Caligaris-Cappio F.: B-CLL: At the crossroad between proliferation and apoptosis. B Cell lymphoproliferative disorders II meeting, 2-5.06.2001, Amsterdam, Abstract Book, 29
10. Carter B.Z., Kornblau S.M., Tsao T., Wang R.Y., Schober W.D., Milella M., Sung H.G., Reed J.C., Andreeff M.: Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood, 2003; 102: 4179-4186
11. Carter B.Z., Milella M., Altieri D.C., Andreeff M.: Cytokine-regulated expression of survivin in myeloid leukemia. Blood, 2001; 97: 2784-2790
12. Che X.F., Zheng C.L., Owatari S., Mutoh M., Gotanda T., Jeung H.C., Furukawa T., Ikeda R., Yamamoto M., Haraguchi M., Arima N., Akiyama S.: Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines. Blood, 2006; 107: 4880-4887
13. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W.: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA, 1997; 94: 10057-10062
14. Collins R.J., Verschuer L.A., Harmon B.V., Prentice R.L., Pope J.H., Kerr J.F.: Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br. J. Haematol., 1989; 71: 343-350
15. Cordone I., Masi S., Mauro F.R., Soddu S., Morsilli O., Valentini T., Vegna M.L., Guglielmi C., Mancini F., Giuliacci S., Sacchi A., Mandelli F., Foa R.: p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood, 1998; 91: 4342-4349
16. de Graaf A.O., van Krieken J.H., Tonnissen E., Wissink W., van de Locht L., Overes I., Dolstra H., de Witte T., van der Reijden B.A., Jansen J.H.: Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br. J. Haematol., 2005; 130: 852-859
17. Dighiero G., Maloum K., Desablens B., Cazin B., Navarro M., Leblay R., Leporrier M., Jaubert J., Lepeu G., Dreyfus B., Binet J.L., Travade P.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N. Engl. J. Med., 1998; 338: 1506-1514
18. Du C., Fang M., Li Y., Li L., Wang X.: Smac, a mitochondrial protein that promotes cytochrom c-dependent caspase activation by eliminating IAP inhibition. Cell, 2000; 102: 33-42
19. Fukuda S., Pelus L.M: Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood, 2001; 98: 2091-2100
20. Garcia J.F., Camacho F.I., Morente M., Fraga M., Montalbán C., Alvaro T., Bellas C., Castano A., Diez A., Flores T., Martin C., Martinez M.A., Mazorra F., Menárguez J., Mestre M.J., Mollejo M., Sáez A.I., Sánchez L., Piris M.A.: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 2003; 101: 681-689
21. Gottardi D., Alfarano A., De Leo A.M., Stacchini A., Aragno M., Rigo A., Veneri D., Zanotti R., Pizzolo G., Caligaris-Cappio F.: In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br. J. Haematol., 1996; 94: 612-618
22. Granziero L., Ghia P., Circosta P., Gottardi D., Strola G., Geuna M., Montagna L., Piccoli P., Chilosi M., Caligaris-Cappio F.: Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood, 2001; 97: 2777-2783
23. Hasegawa T., Suzuki K., Sakamoto C., Ohta K., Nishiki S., Hino M., Tatsumi N., Kitagawa S.: Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood, 2003; 101: 1164-1171
24. Holcik M., Korneluk R.G: XIAP, the guardian angel. Nat. Rev. Mol. Cell Biol., 2001; 2: 550-556
25. Hu Y., Cherton-Horvat G., Dragowska V.: Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res., 2003; 9: 2826-2836
26. Jamroziak K., Robak T.: Cytogenetyka i biologia molekularna przewlekej biaaczki limfatycznej B-komórkowej. Acta Haematol. Pol., 2000; 31: 103-112
27. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 1998; 396: 580-584
28. Liu L., Zhang M., Zou P.: Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk. Lymphoma, 2007; 48: 2179-2183
29. List A.F., Spier C.M., Cline A., Doll D.C., Garewal H., Morgan R., Sandberg A.A.: Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br. J. Haematol., 1991; 78: 28-34
30. Lockshin R.A., Zakeri Z.: Programmed cell death and apoptosis: origins of the theory. Nat. Rev. Mol. Cell Biol., 2001; 2: 545-550
31. Maiese K., Morhan S.D., Chong Z.Z.: Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr. Neurovasc. Res., 2007; 4: 63-71
32. Martinez A., Bellosillo B., Bosch F., Ferrer A., Marce S., Villamor N., Ott G., Montserrat E., Campo E., Colomer D.: Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am. J. Pathol. 2004; 164: 501-510
33. Messineo C., Jamerson M.H., Hunter E., Braziel R., Bagg A., Irving S.G., Cossman J.: Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood, 1998; 91: 2443-2451
34. Mollica S.: Prognostic factors in chronic lymphocytic leukemia. W: Chronic lymphoid leukemias. Red.: Cheson B.D., Marcel Dekker, Inc. New York 2001; 231-260
35. Munzert G., Kirchner D., Stobbe H., Bergmann L., Schmid R.M., Döhner H., Heimpel H.: Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood, 2002; 100: 3749-3756
36. Nachmias B., Ashhab Y., Ben-Yehuda D.: The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin. Cancer Biol., 2004; 14: 231-243
37. Nakagawa Y., Abe S., Kurata M., Hasegawa M., Yamamoto K., Inoue M., Takemura T., Suzuki K., Kitagawa M.: IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am. J. Hematol. 2006; 81: 824-831
38. Nakagawa Y., Yamaguchi S., Hasegawa M., Nemoto T., Inoue M., Suzuki K., Hirokawa K., Kitagawa M.: Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk. Res., 2004; 28: 487-494
39. Reed J.C.: Mechanisms of apoptosis. Am. J. Pathol., 2000; 157: 1415-1430
40. Roliñski J.: Przewleka biaaczka limfocytowa B-komórkowa-zaburzenia proliferacji czy apoptozy. Acta Haematol. Pol., 1998; 29 (Supl.1): 19-24
41. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C.: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J., 1997; 16: 6914-6925
42. Salvesen G.S., Duckett C.S.: IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol., 2002; 3: 401-410
43. Schimmer A.D., Dalili S.: Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am. Soc. Hematol. Educ. Program, 2005; 215-219
44. Schlette E.J., Medeiros L.J., Goy A., Lai R., Rassidakis G.Z.: Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J. Clin. Oncol., 2004; 22: 1682-1688
45. Schliep S., Decker T., Schneller F., Wagner H., Häcker G.: Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia. Exp. Hematol., 2004; 32: 556-562
46. Shi Y.: A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol., 2001; 8: 394-401
47. Silva K.L., Vasconcellos D.V., Castro E.D., Coelho A.M., Linden R., Maia R.C.: Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis, 2006; 11: 277-285
48. Sun C., Cai M., Meadows R.P., Xu N., Gunasekera A.H., Herrmann J., Wu J.C., Fesik S.W.: NMR structure and mutagenesis of the third BIR domain of the inhibitor of apoptosis protein XIAP. J. Biol. Chem, 2000; 275: 33777-33781
49. Suzuki Y., Nakabayashi Y., Takahashi R.: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA, 2001; 98: 8662-8667
50. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., Scudiero D.A., Tudor G., Qui Y.H., Monks A., Andreeff M., Reed J.C.: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res., 2000; 6: 1796-1803
51. Tamm I., Richter S., Oltersdorf D., Creutzig U., Harbott J., Scholz F., Karawajew L., Ludwig W.D., Wuchter C.: High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res., 2004; 10: 3737-3744
52. Tamm I., Richter S., Scholz F., Schmelz K., Oltersdorf D., Karawajew L., Schoch C., Haferlach T., Ludwig W.D., Wuchter C.: XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J., 2004; 5: 489-495
53. Troeger A., Siepermann M., Escherich G., Meisel R., Willers R., Gudowius S., Moritz T., Laws H.J., Hanenberg H., Goebel U., Janka-Schaub G.E., Mahotka C., Dilloo D.: Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica, 2007; 92: 1043-1050
54. van Loo G., van Gurp M., Depuydt B., Srinivasula S.M., Rodriguez I., Alnemri E.S., Gevaert K., Vandekerckhove J., Declercq W., Vandenabeele P.: The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ., 2002; 9: 20-26
55. Vaux D.L., Silke J.: Mammalian mitochondrial IAP binding proteins. Biochem. Biophys. Res. Commun., 2003; 304: 499-504
56. Verhagen A.M., Coulson E.J., Vaux D.L.: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol., 2001; 2: reviews 3009.1-3009.10
57. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L:. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 2000; 102: 43-53
58. Verhagen A.M., Silke J., Ekert P.G., Pakusch M., Kaufmann H., Connolly L.M., Day C.L., Tikoo A., Burke R., Wrobel C., Moritz R.L., Simpson R.J.,. Vaux D.L.: HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem., 2002; 277: 445-454
59. Vousden K.H.: Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta, 2002; 1602: 47-59
60. Vousden K.H,. Lu X.: Live or let die: The cell's response to p53. Nat. Rev. Cancer, 2002; 2: 594-604
61. Vousden K.H., Prives C.: P53 and prognosis: new insights and further complexity. Cell, 2005; 120: 7-10
62. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. Jr.: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998; 281: 1680-1683
63. Wołowiec D.: Regulacja aktywnos̈ci podziałowej komórek przewlekłej białaczki limfatycznej. Acta Haematol. Pol., 2001, 32 (Supl.1): 46-50
64. Wrzesień-Kus̈ A., Smolewski P., Sobczak-Pluta A., Wierzbowska A., Robak T.: The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis, 2004; 9: 705-715
65. Wyllie A.H.. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev., 1992; 11: 95-103
66. Yamamoto K., Abe S., Nakagawa Y., Suzuki K., Hasegawa M., Inoue M., Kurata M., Hirokawa K., Kitagawa M.: Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk. Res., 2004; 28: 1203-1211
67. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D.: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science, 2000; 288: 874-877